Antimicrobial susceptibility and molecular epidemiology of clinical Enterobacter cloacae bloodstream isolates in Shanghai, China

Su Wang1,‡, Shu-Zhen Xiao1,‡, Fei-Fei Gu1, Jin Tang2, Xiao-Kui Guo3, Yu-Xing Ni1, Jie-Ming Qu4,* , Li-Zhong Han1,*

1 Department of Clinical Microbiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 2 Department of Clinical Laboratory, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China, 3 Department of Medical Microbiology and Parasitology, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 4 Department of Pulmonary Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

These authors contributed equally to this work.
‡ These authors are co-first authors on this work.
* hanlizhong1107@163.com (LZH); jmqu0906@163.com (JMQ)

Abstract

Background

Enterobacter cloacae is a major nosocomial pathogen causing bloodstream infections. We retrospectively conducted a study to assess antimicrobial susceptibility and phylogenetic relationships of E. cloacae bloodstream isolates in two tertiary university-affiliated hospitals in Shanghai, in order to facilitate managements of E. cloacae bloodstream infections and highlight some unknowns for future prevention.

Methods

Fifty-three non-duplicate E. cloacae bloodstream isolates were consecutively collected from 2013 to 2016. Antimicrobial susceptibility was determined by disk diffusion. PCR was performed to detect extended-spectrum β-lactamase (ESBL), carbapenemase and colistin resistance (MCR-1) gene. Plasmid-mediated AmpC β-lactamase (pAmpC) genes were detected using a multiplex PCR assay targeting MIR/ACT gene (closely related to chromosomal EBC family gene) and other plasmid-mediated genes, including DHA, MOX, CMY, ACC, and FOX. eBURST was applied to analyze multi-locus sequence typing (MLST).

Results

The rates of resistance to all tested antibiotics were <40%. Among 53 E. cloacae isolates, 8 (15.1%) were ESBL producers, 3(5.7%) were carbapenemase producers and 18(34.0%) were pAmpC producers. ESBL producers bear significantly higher resistance to cefotaxime (100.0%), ceftazidime (100.0%), aztreonam (100.0%), piperacillin (87.5%), tetracycline (75.0%), and trimethoprim-sulfamethoxazole (62.5%) than non-producers (p<0.05). pAmpC- and non-producers both presented low resistance rates (<40%) to all antibiotics (p>0.05). SHV (6/8, 75.0%) and MIR/ACT (15/18, 83.3%) predominated in ESBL and pAmpC producers respectively. Moreover, 2 isolates co-carried TEM-1, SHV-12, IMP-26
and DHA-1. MLST analysis distinguished the 53 isolates into 51 STs and only ST414 and ST520 were assigned two isolates of each (2/53).

**Conclusion**

The antimicrobial resistance rates were low among 53 *E. cloacae* bloodstream isolates in the two hospitals. Multiclonality disclosed no evidence on spread of these isolates in Shanghai. The simultaneous presence of ESBL, carbapenemase and pAmpC detected in 2 isolates was firstly reported in Shanghai, which necessitated active ongoing surveillances and consistent prevention and control of *E. cloacae*.

**Introduction**

*Enterobacter cloacae* is an important emerging pathogen, causing various nosocomial infections, including respiratory infections, bloodstream infections (BSIs) and surgical site infections [1, 2]. BSIs due to multidrug-resistant (MDR) *Enterobacteriaceae* were related to high mortality, sometimes exceeding 50% depending on the study population[3]. *E. cloacae* has become the third most frequent and lethal *Enterobacteriaceae* species involved in BSIs over the past decades[4–6]. Worse than that, MDR *E. cloacae* isolates have been reported widespread, posing a serious threat to empiric therapy[6–9]. An assessment showed global resistance to cefepime increased significantly from 36% in 2004 to 63% in 2014 and 8.5% of *E. cloacae* were MDR in Asia-Pacific Rim, just lower than that in Latin America (14%) [10].

The factors dominantly contributing to resistance among *E. cloacae* maybe the plasmid-mediated AmpC β-lactamases (pAmpC), plasmid-encoded CTX-M family of extended-spectrum β-lactamases(ESBLs), the KPC family of carbapenemases, and metallo β-lactamases of the VIM, IMP, and NDM-1 types[6, 11]. Production of ESBLs and pAmpC by *E. cloacae* were continuously documented worldwide [12]. For example, 42% *E. cloacae* bloodstream isolates were screened as ESBL positive in Brazil with CTX-M-15 the most common type [13]. In Australia, IMP-producing *E. cloacae* has been noted to be the predominant form of carbapenemase-producing *Enterobacteriaceae* (CPE) [14].

These sporadic cases of previously discovered enzymes and new reports of resistant genes necessitated resistance surveillance and molecular characterization on *E. cloacae* to identify potentially endemic resistance genes before their spread. Nevertheless, scarce data on susceptibility and molecular epidemiology of *E. cloacae* causing BSIs were available in Shanghai, even in China. This study, therefore, is to give a broad scope on the antimicrobial susceptibility and the presence of resistance genes and their relationships with sequence types (STs) among local *E. cloacae* bloodstream isolates. It was the first study on phenotypic and molecular properties of these isolates in Shanghai.

**Materials and methods**

**Setting and isolates**

This study was conducted in two comprehensive tertiary university-affiliated hospitals (Hospital A and B). They served a local population of around 1.8 million, located in Huangpu District (Hospital A, 1800 beds) and Xuhui District (Hospital B, 1950 beds) respectively. Fifty-three consecutive and non-duplicate *E. cloacae* isolates were collected from January 2013 to June 2016 (34 from Hospital A and 19 from Hospital B). All isolates were recovered from blood and re-identified using Matrix Assisted Laser Desorption Ionization-Time of Flight mass...
spectrometry (MALDI-TOF MS) (bioMérieux, Mar-cyl’Étoile, France) combining with classical biochemical tube tests (Melibiose fermentation test)[15]. The study was approved by Ruijin Hospital Ethics Committee (Shanghai Jiao Tong University School of Medicine), and the Review Board exempted request for informed consent because our study only focused on the bacteria and no patient-level data were involved.

**Antimicrobial susceptibility testing**

Antimicrobial susceptibility of the *E. cloacae* isolates were determined by the disk diffusion as recommended by CLSI [16]. The antibiotics tested were piperacillin, piperacillin-tazobactam, cefepime, cefotaxime, ceftazidime, imipenem, meropenem, ertapenem, amikacin, gentamicin, sulfamethoxazole-trimethoprim, ciprofloxacin, levofloxacin, tetracycline, tigecycline and polymyxin B. Results were interpreted according to CLSI criteria (M100S 26th Edition)[16]. For tigecycline, the result was interpreted using the European Committee On Antimicrobial Susceptibility Testing (EUCAST) criteria (2017 Ver. 7.0)[17]; for polymyxin B, the result was interpreted using the Antibiogram Committee of the French Society for Microbiology criteria (CASFM 2013 Ver. June [http://www.sfm-microbiologie.org/UserFiles/files/casfm/CASFM2013vjuin.pdf]). *Escherichia coli* ATCC 25922 was used for quality control.

**Detection of resistance genes**

Polymerase chain reaction (PCR) was performed to confirm the existence of ESBL genes (*bla*TEM, *bla*SHV, *bla*CTX-M (-1,-9 group), *bla*OXA (-1,-2,-10 group), *bla*VEB, *bla*GES, and *bla*PER), carbapenemase genes (*bla*VIM, *bla*IMP, *bla*KPC, *bla*OXA-48, and *bla*NDM) and plasmid-mediated colistin resistance gene (*mcr-1*), using primers previously described [18, 19]. The presence of pAmpC genes was detected using a multiplex PCR assay targeting MIR/ACT (closely related with chromosomal EBC family gene) and other plasmid-mediated genes, including DHA, MOX, CIT, ACC and FOX, as described by Pérez-Pérez and Hanson[20]. Positive amplicons were bidirectional sequenced and aligned with subtypes of resistance genes in GenBank (http://blast.ncbi.nlm.nih.gov/BLAST).

**MLST**

A multilocus sequence typing (MLST) scheme was used to assign *E. cloacae* isolates to clonal lineages, including seven conserved housekeeping genes (*dnaA*, *fusA*, *gyrB*, *levS*, *pyrG*, *rplB*, and *rpoB*) as described by Miyoshi-Akiyama et al.[21]. The combination of seven alleles can define the ST for one isolate according to the MLST website (http://pubmlst.org/ecloacae/). STs not found in the database were submitted. The eBURST version 3.0 was used to analyze the clustering of related STs. The eBURST algorithm can group strains according to their allelic profiles by employing a user-specified group definition, as well as drawing a rough sketch to show the genetic relationship[22]. In this study, if 6 of the 7 alleles were homologous, strains would be grouped together.

**Statistical analysis**

SAS 8.2 (SAS Institute Inc., Cary, NC, USA) was used for statistical analysis. Continuous variables were presented as median and interquartile range. The chi-square or Fisher’s exact test was used to compare the discrepancy between different groups for categorical variables. Differences were considered statistically significant at a two-tailed *P* value of <0.05.
Results

Clinical data

The age of the 53 patients ranged from 23 to 86 years (median age: 59.4 years, interquartile range: 50–70 years). Male patients (37/53) were more than females (16/53). Near half of the episodes were derived from the surgery (22/53), and where most patients suffered from malignant tumor (10/22) (S1 Table).

Antimicrobial susceptibility testing

As summarized in Table 1, the rates of resistance to all tested antibiotics were <40% and cefotaxime exhibited the highest resistance (37.7%). Among 53 E. cloacae isolates, 8(15.1%) were ESBL producers, 3(5.7%) were carbapenemase producers and 18(34.0%) were pAmpC producers (Table 2). The highest resistance rates of ESBL producers were to cefotaxime (100.0%), ceftazidime (100.0%), aztreonam (100.0%), piperacillin (87.5%), tetracycline (75.0%), and trimethoprim-sulfamethoxazole (62.5%). Simultaneously, ESBL producers bear significantly higher resistance to them than non-producers (P<0.05). Of note, pAmpC- and non-producers both presented low resistance rates (<40%) to all antibiotics, which did not differ significantly in the two groups (P>0.05) (Table 1).

Resistance genes

Of the 8 ESBL producers, SHV enzymes (6, 75.0%) predominated with all identified as SHV-12, and CTX-M enzymes (2, 25.0%) followed, including CTX-M-15(1, 50.0%) and CTX-M-65 (1, 50.0%) (Table 2). A total of 18 (34.0%) of 53 E. cloacae isolates were positive for pAmpC genes, of which 15 (83.3%) isolates were detected with MIR/ACT gene and the other 3 (16.7%) isolates were positive for other pAmpC genes.

Table 1. Rates of antimicrobial resistance in 53 E. cloacae bloodstream isolates.

| Antibiotics            | Total (N = 53) | ESBL (N = 8) | non-ESBL (N = 45) | P    | Total (N = 53) | pAmpC (N = 18) | non-pAmpC (N = 35) | P    |
|------------------------|----------------|--------------|-------------------|------|----------------|-------------------|-------------------|------|
| piperacillin           | 16 (30.2)      | 7 (87.5)     | 9 (20.0)           | 0.0006 | 16 (30.2)      | 5 (27.8)         | 11 (31.4)         | 0.7839 |
| piperacillin-tazobactam | 6 (11.3)       | 2 (25.0)     | 4 (8.9)            | 0.2195 | 6 (11.3)       | 2 (11.1)         | 4 (11.4)          | 1.0000 |
| aztreonam              | 18 (34.0)      | 8 (100.0)    | 10 (22.2)          | 0.0001 | 18 (34.0)      | 6 (33.3)         | 12 (34.3)         | 0.9447 |
| cefepime               | 7 (13.2)       | 4 (50.0)     | 3 (6.7)            | 0.0056 | 7 (13.2)       | 4 (22.2)         | 3 (8.6)           | 0.3362 |
| imipenem               | 1 (1.9)        | 1 (12.5)     | 0 (0.0)            | 0.1509 | 1 (1.9)        | 0 (0.0)          | 1 (2.9)           | 1.0000 |
| meropenem              | 3 (5.7)        | 3 (37.5)     | 0 (0.0)            | 0.0024 | 3 (5.7)        | 2 (11.1)         | 1 (2.9)           | 0.5459 |
| ertapenem              | 3 (5.7)        | 3 (37.5)     | 0 (0.0)            | 0.0024 | 3 (5.7)        | 2 (11.1)         | 1 (2.9)           | 0.5459 |
| tigecycline            | 2 (3.8)        | 0 (0.0)      | 2 (4.4)            | 1.0000 | 2 (3.8)        | 0 (0.0)          | 2 (5.7)           | 0.5428 |
| gentamicin             | 5 (9.4)        | 4 (50.0)     | 1 (2.2)            | 0.0011 | 5 (9.4)        | 4 (22.2)         | 1 (2.9)           | 0.0738 |
| amikacin               | 2 (3.8)        | 2 (25.0)     | 0 (0.0)            | 0.0203 | 2 (3.8)        | 2 (11.1)         | 0 (0.0)           | 0.1110 |
| tetracycline           | 8 (15.1)       | 6 (75.0)     | 2 (4.4)            | <.0001 | 8 (15.1)       | 5 (27.8)         | 3 (8.6)           | 0.1486 |
| ciprofloxacin          | 2 (3.8)        | 2 (25.0)     | 0 (0.0)            | 0.0203 | 2 (3.8)        | 1 (5.6)          | 1 (2.9)           | 1.0000 |
| levofloxacin           | 2 (3.8)        | 2 (25.0)     | 0 (0.0)            | 0.0203 | 2 (3.8)        | 1 (5.6)          | 1 (2.9)           | 1.0000 |
| sulfamethoxazole-trimethoprim | 10 (18.9) | 5 (62.5)     | 5 (11.1)           | 0.0034 | 10 (18.9)      | 6 (33.3)         | 4 (11.4)          | 0.1189 |
| ceftriaxime            | 16 (30.2)      | 8 (100.0)    | 8 (17.8)           | <.0001 | 16 (30.2)      | 6 (33.3)         | 10 (28.6)         | 0.7206 |
| cefotaxime             | 20 (37.7)      | 8 (100.0)    | 12 (26.7)          | 0.0004 | 20 (37.7)      | 7 (38.9)         | 13 (37.1)         | 0.9012 |
| polymyxin B            | 8 (11.9)       | 1 (12.5)     | 4 (8.9)            | 0.5743 | 8 (11.9)       | 2 (11.1)         | 3 (8.6)           | 1.0000 |

https://doi.org/10.1371/journal.pone.0189713.t001
were detected with DHA-1 gene (Table 2). Of the 15 MIR/ACT producers, the dominant was ACT (12, 80.0%), and MIR (3, 20.0%) followed. The most common subtypes of ACT were ACT-20 (5, 41.7%) and ACT-3 (3, 25.0%). There were also 3 carbapenemase producers (1 NDM-1 and 2 IMP-26 producers) co-carrying SHV-12 (Table 3). Besides, 5 TEM-1-producing isolates were also identified. No \( \text{bla}_{OXA} \), \( \text{bla}_{VEB} \), \( \text{bla}_{GES} \), \( \text{bla}_{PER} \), \( \text{bla}_{VIM} \), \( \text{bla}_{KPC} \), \( \text{bla}_{OXA-48} \) and \( \text{bla}_{mcr-1} \) were detected.

### MLST

MLST analysis distinguished 51 different STs, clustered into 3 non-overlapping clonal complexes (CCs) and 43 singletons (Fig 1). Only ST414 (2/53) and ST520 (2/53) were isolated two of each ST, while the others were assigned to an isolate per ST (Table 3). Fifteen STs (ST852 to 856, ST860 to 866, ST870 to 872) were newly identified whose sequences have been submitted to the database (https://pubmlst.org/bigsdb?db=pubmlst_ecloacae_seqdef). It was indicated in Table 3 that 5 isolates harbored two or more types of enzymes, including ST133 (SHV-12 and ACT-20), ST418 (TEM-1, SHV-12 and NDM-1), ST177 (CTX-M-65 and ACT-20), ST191 and ST528 (TEM-1, SHV-12, IMP-26 and DHA-1).

### Discussion

*Enterobacter cloacae* was frequently implicated in nosocomial infections[1, 2], and the production of pAmpC, ESBLs and carbapenemases have also led to the multidrug-resistance and high potential dissemination of clinical *Enterobacter cloacae* isolates[23, 24]. Reports on MDR *Enterobacter cloacae* worsening clinical outcome and prolonging hospitalization duration have been alarmingly increasing.
Table 3. Antimicrobial resistance profiles and genotypes in MLST of 53 *E. cloacae* isolates from bloodstream infections.

| ST   | Total number | Hospital | Resistance genes | Antimicrobial resistance profiles |
|------|--------------|----------|-----------------|----------------------------------|
|      |              |          | ESBL Carbapenemase EBC DHA Others                  |                                  |
| ST414| 2            | B        | SHV-12          | PRL-ATM-GM-TE-CAZ-CTX             |
|      |              |          | A               | TEM-1 PRL-FEP-CTX                 |
| ST520| 2            | A        |                 |                                  |
| ST22 | 1            | B        | ACT-3           | -                                |
| ST32 | 1            | B        |                 | ATM-CAZ-CTX-PB                   |
| ST41 | 1            | A        | MIR-1           | -                                |
| ST45 | 1            | A        |                 |                                  |
| ST46 | 1            | B        |                 | TGC                              |
| ST62 | 1            | B        |                 | PRL-ATM-SXT-CTX                  |
| ST65 | 1            | B        | ACT-20          | -                                |
| ST78 | 1            | A        |                 | -                                |
| ST84 | 1            | A        |                 | -                                |
| ST88 | 1            | B        |                 |                                  |
| ST113| 1            | A        | ACT-20          | TZP-GM-TE-SXT                    |
| ST114| 1            | B        |                 | -                                |
| ST118| 1            | B        | ACT-21          | -                                |
| ST133| 1            | A        | SHV-12          | PRL-ATM-TE-SXT-CAZ-CTX           |
| ST175| 1            | A        |                 | PRL-SXT-CTX                      |
| ST177| 1            | A        | CTX-65          | ACT-20 TEM-1 PRL-ATM-FEP-GM-TE-LEV-SXT-CAZ-CTX |
| ST191| 1            | A        | SHV-12 IMP-26   | DHA-1 TEM-1 PRL-ATM-FEP-MEM-ETP-GM-TE-SXT-CAZ-CTX |
|      |              |          | IMP-26 DHA      | TEM-1 PRL-ATM-FEP-MEM-ETP-GM-TE-SXT-CAZ-CTX |
| ST254| 1            | A        | SHV-12 IMP-26   | DHA-1 TEM-1 PRL-ATM-FEP-MEM-ETP-GM-TE-SXT-CAZ-CTX |
| ST279| 1            | A        | CTX-15          | PRL-TZP-ATM-CAZ-CTX              |
| ST318| 1            | A        | CTX-15          | PRL-TZP-ATM-CAZ-CTX-PB           |
| ST365| 1            | A        | CTX-15          | -                                |
| ST418| 1            | A        | SHV-12 NDM-1    | TEM-1 PRL-TZP-ATM-FEP-IPM-MEM-ETP-TE-CIP-LEV-SXT-CAZ-CTX |
| ST422| 1            | A        | SHV-12 NDM-1    | TEM-1 PRL-TZP-ATM-FEP-IPM-MEM-ETP-TE-CIP-LEV-SXT-CAZ-CTX |
| ST524| 1            | A        | SHV-12 IMP-26   | DHA-1 TEM-1 PRL-ATM-FEP-MEM-ETP-GM-TE-SXT-CAZ-CTX |
| ST528| 1            | A        | SHV-12 IMP-26   | DHA-1 TEM-1 PRL-ATM-FEP-MEM-ETP-GM-TE-SXT-CAZ-CTX |
| ST533| 1            | B        |                 | -                                |
| ST536| 1            | A        |                 | PRL-ATM-CAZ-CTX                  |
| ST562| 1            | A        | ACT-3           | -                                |
| ST584| 1            | B        |                 | -                                |
| ST636| 1            | B        |                 | ATM                              |
| ST691| 1            | B        |                 | -                                |
| ST718| 1            | B        |                 | -                                |
| ST744| 1            | A        | SHV-12          | ATM-CAZ-CTX                      |
| ST777| 1            | A        |                 | -                                |
| ST852| 1            | A        |                 | PRL-ATM-TE-SXT-CAZ-CTX           |

(Continued)
since 21st century[7–9]. Our study showed most of the isolates remained susceptible to all tested antibiotics, but ESBL producers held significantly higher resistance to sulfamethoxazole/trimethoprim and cephalosporins (Table 1). Regarding the clinical characteristics, E. cloacae bloodstream isolates harboring resistant genes were mostly associated with elderly patients from the surgery or Intensive Care Unit (S1 Table). This also necessitated the cooperative ongoing monitoring on phylogenetic screening and investigation of novel treatments especially for immunocompromised patients to prevent possible expansion of MDR E. cloacae isolates.

Of all E. cloacae isolates enrolled, 15.1% (8/53) produced ESBL, which was higher than that in north-eastern USA (10.1%)[3], and pretty higher than that reported by a surveillance conducted in Europe and the USA from 1999 to 2004 with ~5% ESBL-producing Enterobacter spp. collected from all sites[12]. Unlike CTX-M-producers most frequent in Latin American countries[13], SHV was the dominant ESBL type with all identical to type 12 in this study (Table 2). The proportion of SHV (75.0%) was higher than that in Guangdong China (58%)[23], and similar to that in Tunisia (77.8%)[24]. SHV-12, one of the most prevalent SHV types in Asia, can confer resistance against β-lactams, fluoroquinolones, aminoglycosides and sulfonamides, and its location and transmission efficiency were correlated closely with the antibiotic resistance of E. cloacae[23]. What’s worse, the coexistence of carbapenemase and/or pAmpC were detected among over half of the SHV-12-producers (4/6) in our study (Table 3), warranting long-term monitoring on phylogenetic screening and prudent use of antibiotics. Additionally, several reports have found some spreading subclones (ST66, ST78 and ST114) especially ST114, were specifically associated with CTX-M production[25, 26], while in our study only ST78 and ST114 were identified, and both susceptible to all tested antibiotics (Table 3).

### Table 3. (Continued)

| ST  | Total number | Hospital | Resistance genes | Antimicrobial resistance profiles |
|-----|--------------|----------|------------------|----------------------------------|
|     |              |          | ESBL Carbapenemase EBC DHA Others |
| ST853 | 1 | A | | |
| ST854 | 1 | A | | |
| ST855 | 1 | A | | |
| ST856 | 1 | A | ACT-20 | PRL-TZP-ATM-FEP-CAZ-CTX |
| ST860 | 1 | B | ACT-13 | |
| ST861 | 1 | B | ACT-8 | |
| ST862 | 1 | B | | PRL-ATM-TGC-CAZ-CTX |
| ST863 | 1 | B | | DHA-1 |
| ST864 | 1 | B | | |
| ST865 | 1 | A | ACT-38 | ATM-CAZ-CTX |
| ST866 | 1 | A | | PRL-TZP-ATM-FEP-CAZ-CTX |
| ST870 | 1 | A | MIR-1 | PB |
| ST871 | 1 | A | ACT-3 | SXT-CTX-PB |
| ST872 | 1 | A | | |

PRL, piperacillin; TZP, piperacillin-tazobactam; ATM, aztreonam; FEP, cefepime; IPM, imipenem; MEM, meropenem; ETP, ertapenem; TGC, tigecycline; GM, gentamicin; AK, amikacin; TE, tetracycline; CIP, ciprofloxacin; LEV, levofloxacin; SXT, trimethoprim-sulfamethoxazole; CAZ, ceftazidime; CTX, cefotaxime; PB, polymyxin B.

https://doi.org/10.1371/journal.pone.0189713.t003
Besides, distributions of these resistant genes were different in Hospital A and B (Table 2), which suggested that different resistance genes may exhibit geographic difference among *E. cloacae* isolates due to various modes of transmission.

PAmpC can preferentially hydrolyze all β-lactams except fourth-generation cephalosporins and carbapenems and may serve as the reservoir for the emergence of antibiotic resistance [27]. The high proportion of MIR/ACT (83.3%) in pAmpC producers (Table 2) was not surprising as it has been reported as the most predominant AmpC gene in the Asia-Pacific area (77.8%) [28]. It is noteworthy the simultaneous production of pAmpC and other β-lactamases in four isolates (ST177, ST191, ST418 and ST528) (as observed in Table 3 with decreased susceptibility to cefepime) could cause quick acquisition and potential spread of transferable resistance determinants and thus complicate the therapeutic treatment for the infections. Factually, the resistance to cefepime could be associated with the presence of SHV-12 or CTX-65, despite in addition to pAmpC, other mechanisms such as TEM-1 alteration or overexpression and/or porin loss could be involved [2, 29], and further molecular studies were demanded. The co-carriage of ESBL, carbapenemase and pAmpC in *E. cloacae* was once reported in Taiwan [30], but firstly in Shanghai.

Carbapenemase spread has been increasingly reported worldwide over the last decade [31]. We found one carbapenemase producer (ST418, NDM-1) carried TEM-1 and SHV-12 as well, and the other two (ST191 and ST528, IMP-26) co-carried TEM-1, SHV-12 and DHA-1 (Table 3). Australia has observed an increasing incidence of CRE with the majority being IMP producers [14], which agreed with current study, but the prevailing subtypes were not the same in different regions [14, 30]. IMP-26 was first reported in a *Pseudomonas aeruginosa* isolate in...
Singapore [32] and few reports appeared later about IMP-26-producing isolates especially *E. cloacae* isolates, but interestingly, the two IMP-producers in our study were both detected as IMP-26. It was still noted that IMP-producing *E. cloacae* had caused several outbreaks or possible spread in other countries [14, 33, 34], so we should keep continuously monitoring of carbapenems resistance and carbapenemase productions among *E. cloacae*. NDM-1 was the dominant carbapenemase of carbapenems-resistant *E. cloacae* in Henan China, and in contrast to VIM-1 the most prevalent in Spain and other southern Europe [35, 36]; while only one NDM-1-producer and none VIM-1-producer were found in current study.

A clonality study of *E. cloacae* has once denoted the association of distinct clonal groups with genetic lineages of higher prevalence and/or wider geographical spread [25]. However, our study has only demonstrated local *E. cloacae* bloodstream isolates did not evolve from a unique ancestral background with 51 STs distinguished from 53 isolates and 8 isolates (15.1%) assigned to 3 CCs (Fig 1). STs harboring two or three types of enzymes shared no alleles in common with each other (Table 3, Fig 1). This implied no clonal dissemination in the region.

There may be one limitation in this study: many hospitals do not preserve clinical isolates regularly in China, so our conclusion based on two hospitals may not be generalizable enough or extrapolated directly to the whole region. However, it provides the step stone for future national researches associated with cooperative surveillance on resistance and resistant mechanisms to control potential further dissemination.

### Conclusions

Our study described the phenotypic and molecular properties of *E. cloacae* bloodstream isolates in Shanghai for the first time. Based on the few isolates analyzed, it was noted that antimicrobial resistance was low among them. The simultaneous presence of ESBL, carbapenemase and pAmpC genes detected in 2 *E. cloacae* bloodstream isolates was first reported in Shanghai. Genetic diversity revealed no evidence suggesting a spread of these isolates. Active long-term surveillance should be continuously implemented on antimicrobial resistance and consistent prevention and control of *E. cloacae*.

### Supporting information

S1 Table. Clinical data, rates of drug resistance and molecular characteristics of 53 *E. cloacae* from bloodstream infections.
(XLSX)

### Acknowledgments

We would like to thank Qiong Wu for the preparation of the isolates, and the Department of Medical Microbiology and Parasitology at the School of Medicine of Shanghai Jiao Tong University for excellent laboratory provision and technical assistance.

### Author Contributions

**Conceptualization:** Shu-Zhen Xiao, Li-Zhong Han.

**Data curation:** Su Wang, Shu-Zhen Xiao, Fei-Fei Gu, Jin Tang.

**Formal analysis:** Su Wang.

**Funding acquisition:** Yu-Xing Ni.

**Investigation:** Fei-Fei Gu.
Methodology: Shu-Zhen Xiao, Xiao-Kui Guo.
Project administration: Li-Zhong Han.
Resources: Su Wang, Jin Tang, Xiao-Kui Guo, Yu-Xing Ni.
Supervision: Li-Zhong Han.
Writing – original draft: Su Wang, Jie-Ming Qu, Li-Zhong Han.

References
1. Sanders WE Jr., Sanders CC. *Enterobacter* spp.: pathogens poised to flourish at the turn of the century. Clinical microbiology reviews. 1997; 10(2):220–41. Epub 1997/04/01. PMID: 9105752; PubMed Central PMCID: PMCPMC1729117.
2. Babouee Flury B, Ellington MJ, Hopkins KL, Turton JF, Dournih M, Loj R, et al. Association of Novel Nonsynonymous Single Nucleotide Polymorphisms in ampD with Cephalosporin Resistance and Phylogenetic Variations in *ampC, ampR, ompF*, and *ompC* in *Enterobacter cloacae* Isolates That Are Highly Resistant to Carbapenems. Antimicrobial agents and chemotherapy. 2016; 60(4):2383–90. Epub 2016/02/10. https://doi.org/10.1128/AAC.02835-15 PMID: 26856839; PubMed Central PMCID: PMCPMC4808197.
3. Qureshi ZA, Paterson DL, Pakstis DL, Adams-Haduch JM, Sandkovsky G, Sordillo E, et al. Risk factors and outcome of extended-spectrum beta-lactamase-producing *Enterobacter cloacae* bloodstream infections. International journal of antimicrobial agents. 2011; 37(1):26–32. https://doi.org/10.1016/j.ijantimicag.2010.09.009 PMID: 21075605.
4. Davin-Regli A, Pages JM. *Enterobacter aerogenes* and *Enterobacter cloacae*: versatile bacterial pathogens confronting antibiotic treatment. Frontiers in microbiology. 2015; 6:392. Epub 2015/06/05. https://doi.org/10.3389/fmicb.2015.00392 PMID: 26042091; PubMed Central PMCID: PMCPMC4435039.
5. Guanghui L, Demei Z, Fu W, Zhidong H, Quan L, Ziyong S, et al. The distribution and antibiotic resistance of clinical isolates from blood culture in 2012 CHINET surveillance program in China. Chin J Infect Chemother. 2014; 14(6):474–81. Epub 481. https://doi.org/10.3969/j.issn.1009-7708.2014.06.003
6. Chen CH, Huang CC. Risk factor analysis for extended-spectrum beta-lactamase-producing *Enterobacter cloacae* bloodstream infections in central Taiwan. BMC infectious diseases. 2013; 13:417. Epub 2013/09/10. https://doi.org/10.1186/1471-2334-13-417 PMID: 24010678; PubMed Central PMCID: PMCPMC3846452.
7. Bush K. Alarming beta-lactamase-mediated resistance in multidrug-resistant *Enterobacteriaceae*. Current opinion in microbiology. 2010; 13(5):558–64. Epub 2010/10/06. https://doi.org/10.1016/j.mib.2010.09.006 PMID: 20920882.
8. Potter RF, D’Souza AW, Dantas G. The rapid spread of carbapenem-resistant *Enterobacteriaceae*. Drug Resist Updat. 2016; 29:30–46. https://doi.org/10.1016/j.drup.2016.09.002 PMID: 27912842; PubMed Central PMCID: PMCPMC5140036.
9. Yuan L, Yun L, Feng X. Mohnarin report of 2011–2012: surveillance for resistance of bacteria causing bloodstream infections Chin J Clin Pharmacol 2014; 30(03):278–88.
10. Gianniano C, Caia C, Fasciana T, Dowzicky MJ. Global Assessment of the Activity of Tigecycline against Multidrug-Resistant Gram-Negative Pathogens between 2004 and 2014 as Part of the Tigecycline Evaluation and Surveillance Trial. mSphere. 2017; 2(1). Epub 2017/01/27. https://doi.org/10.1128/mSphere.00310-16 PMID: 28124025; PubMed Central PMCID: PMCPMC5244261.
11. Girlich D, Poirel L, Nordmann P. Clonal distribution of multidrug-resistant *Enterobacter cloacae*. Diagnostic microbiology and infectious disease. 2015; 81(4):264–8. Epub 2014/11/20. https://doi.org/10.1016/j.diagmicrobio.2015.11.003 PMID: 25680336.
12. Goossens H, Graben A. Prevalence and antimicrobial susceptibility data for extended-spectrum beta-lactamase- and AmpC-producing *Enterobacteriaceae* from the MYSTIC Program in Europe and the United States (1997–2004). Diagnostic microbiology and infectious disease. 2005; 53(4):257–64. Epub 2005/12/20. https://doi.org/10.1016/j.diagmicrobio.2005.10.001 PMID: 1636049.
13. Seki LM, Pereira PS, de Souza Conceição M, Souza MJ, Marques EA, Carballido JM, et al. Molecular epidemiology of CTX-M producing *Enterobacteriaceae* isolated from bloodstream infections in Rio de Janeiro, Brazil: emergence of CTX-M-15. The Brazilian journal of infectious diseases: an official publication of the Brazilian Society of Infectious Diseases. 2013; 17(6):640–6. Epub 2013/09/24. https://doi.org/10.1016/j.bjid.2013.03.012 PMID: 24055309.
14. Sidjabat HE, Townell N, Ninno GR, George NM, Robson J, Vohra R, et al. Dominance of IMP-4-producing *enterobacter cloacae* among carbapenemase-producing *Enterobacteriaceae* in Australia.
Antimicrobial agents and chemotherapy. 2015; 59(7):4059–66. Epub 2015/04/29. https://doi.org/10.1128/AAC.04378-14 PMID: 25918153; PubMed Central PMCID: PMCPMC4468659.

15. FORSYTHE SJ, ABBOTT SL, PITOUT J. Manual Clinical Microbiology, 11th Edition. 11th ed. CARROLL KC, FUNKE G, editors. Washington, DC: American Society for Microbiology (ASM) Press; 2015. 722–5 p.

16. Institute CaLS. Performance Standards for Antimicrobial Susceptibility Testing; 26th Edition M100S. Wayne, PA2016.

17. European Committee On Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 7.0. 2017. [updated 2017.1.1]. Available from: http://www.eucast.org/clinical_breakpoints/.

18. Wang S, Zhao SY, Xiao SZ, Gu FF, Liu QZ, Tang J, et al. Antimicrobial Resistance and Molecular Epidemiology of Escherichia coli Causing Bloodstream Infections in Three Hospitals in Shanghai, China. PloS one. 2016; 11(1):e0147740. https://doi.org/10.1371/journal.pone.0147740 PMID: 26824702; PubMed Central PMCID: PMCPMC4733056.

19. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. The Lancet Infectious diseases. 2016; 16(2):161–8. https://doi.org/10.1016/S1473-3099(15)00424-7 PMID: 26603172.

20. Perez-Perez FJ, Hanson ND. Detection of Plasmid-Mediated AmpC-Lactamase Genes in Clinical Isolates by Using Multiplex PCR. Journal of clinical microbiology. 2002; 40(6):2153–62. https://doi.org/10.1128/JCM.40.6.2153-2162.2002 PMID: 12037080

21. Miyoshi-Akiyama T, Hayakawa K, Ohmagari N, Shimojima M, Kirikae T. Multilocus sequence typing (MLST) for characterization of Enterobacter cloacae. PloS one. 2013; 8(6):e66358. https://doi.org/10.1371/journal.pone.0066358; PubMed Central PMCID: PMCPMC3679064.

22. Feil EJ, Li BC, Aanensen DM, Hanage WP, Spratt BG. eBURST: Inferring Patterns of Evolutionary Descent among Clusters of Related Bacterial Genotypes from Multilocus Sequence Typing Data. Journal of Bacteriology. 2004; 186(5):1518–30. https://doi.org/10.1128/JB.186.5.1518-1530.2004 PMID: 14973027

23. Liu J, Li GM, Lin LY, Wu XL, Huang SL, Zhou Y, et al. Association of antibiotic resistance with SHV-12 extended-spectrum beta-lactamase in Enterobacter cloacae. Experimental and therapeutic medicine. 2016; 11(1):269–76. Epub 2016/02/19. https://doi.org/10.3892/etm.2015.2851 PMID: 26889253; PubMed Central PMCID: PMCPMC4727147.

24. Lahlaoui H, Anis BH, Mohamed K, Mohamed BM. Emergence of SHV-12 extended spectrum beta-lactamase among clinical isolates of Enterobacter cloacae in Tunisia. Microbial pathogenesis. 2012; 53(2):64–5. Epub 2012/05/01. https://doi.org/10.1016/j.micpath.2012.04.003 PMID: 22543154.

25. Izdebski R, Baraniak A, Herda M, Flett J, Bonten MJ, Carmeli Y, et al. MLST reveals potentially high-risk international clones of Enterobacter cloacae. The Journal of antimicrobial chemotherapy. 2015; 70(1):48–54. Epub 2014/09/14. https://doi.org/10.1093/jac/dku359 PMID: 25216820.

26. Haenni M, Saras E, Ponsin C, Dahmen S, Petitjean M, Hoquet D, et al. High prevalence of international ESBL CTX-M-15-producing Enterobacter cloacae ST114 clone in animals. The Journal of antimicrobial chemotherapy. 2016; 71(6):1497–500. Epub 2016/02/07. https://doi.org/10.1093/jac/dkw006 PMID: 26850716.

27. Gude MJ, Seral C, Saenz Y, Guboladla R, Gonzalez-Dominguez M, Torres C, et al. Molecular epidemiology, resistance profiles and clinical features in clinical plasmid-mediated AmpC-producing Enterobacteriaceae. International journal of medical microbiology: IJMM. 2013; 303(8):553–7. https://doi.org/10.1016/j.ijm.2013.07.007 PMID: 23999104.

28. Sheng WH, Badal RE, Hsueh PR, Program S. Distribution of extended-spectrum beta-lactamas, AmpC beta-lactamas, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrobial agents and chemotherapy. 2013; 57(7):2981–8. https://doi.org/10.1128/AAC.00971-12 PMID: 23587958; PubMed Central PMCID: PMCPMC3697370.

29. Guerin F, Isnard C, Cattovir G, Giard JC. Complex Regulation Pathways of AmpC-Mediated beta-Lactam Resistance in Enterobacter cloacae Complex. Antimicrobial agents and chemotherapy. 2015; 59(12):7753–61. Epub 2015/10/07. https://doi.org/10.1128/AAC.01729-15 PMID: 26438498; PubMed Central PMCID: PMCPMC4649247.

30. Wang JT, Wu UI, Lauderdale TL, Chen MC, Li SY, Hsu LY, et al. Carbapenem-nonsusceptible Enterobacteriaceae in Taiwan. PloS one. 2015; 10(3):e0121668. Epub 2015/03/21. https://doi.org/10.1371/journal.pone.0121668 PMID: 25794144; PubMed Central PMCID: PMCPMC4368706.

31. Poirel L, Pitout JD, Nordmann P. Carbapenemases: molecular diversity and clinical consequences. Future Microbiol. 2007; 2(5):501–12. https://doi.org/10.2217/17460913.2.5.501 PMID: 17927473.
32. Koh TH, Khoo CT, Tan TT, Arshad MA, Ang LP, Lau LJ, et al. Multilocus sequence types of carbapenem-resistant *Pseudomonas aeruginosa* in Singapore carrying metallo-beta-lactamase genes, including the novel bla(IMP-26) gene. Journal of clinical microbiology. 2010; 48(7):2563–4. Epub 2010/05/14. https://doi.org/10.1128/JCM.01905-09 PMID: 20463166; PubMed Central PMCID: PMCPMC2897496.

33. Hayakawa K, Miyoshi-Akiyama T, Kirikae T, Nagamatsu M, Shimada K, Mezaki K, et al. Molecular and epidemiological characterization of IMP-type metallo-beta-lactamase-producing *Enterobacter cloacae* in a Large tertiary care hospital in Japan. Antimicrobial agents and chemotherapy. 2014; 58(6):3441–50. https://doi.org/10.1128/AAC.02652-13 PMID: 24709261; PubMed Central PMCID: PMCPMC4068452.

34. Tzouvelekis LS, Markogiannakis A, Psychogiou M, Tassios PT, Daikos GL. Carbapenemases in *Klebsiella pneumoniae* and other *Enterobacteriaceae*: an evolving crisis of global dimensions. Clinical microbiology reviews. 2012; 25(4):682–707. Epub 2012/10/05. https://doi.org/10.1128/CMR.05035-11 PMID: 23034326; PubMed Central PMCID: PMCPMC3485753.

35. Liu C, Qin S, Xu H, Xu L, Zhao D, Liu X, et al. New Delhi Metallo-beta-Lactamase 1 (NDM-1), the Dominant Carbapenemase Detected in Carbapenem-Resistant *Enterobacter cloacae* from Henan Province, China. PloS one. 2015; 10(8):e0135044. https://doi.org/10.1371/journal.pone.0135044 PMID: 26263489; PubMed Central PMCID: PMCPMC4532496.

36. Villa J, Viedma E, Branas P, Orellana MA, Otero JR, Chaves F. Multiclonal spread of VIM-1-producing *Enterobacter cloacae* isolates associated with In624 and In488 integrons located in an IncHI2 plasmid. International journal of antimicrobial agents. 2014; 43(5):451–5. https://doi.org/10.1016/j.ijantimicag.2014.02.006 PMID: 24702943.